Catalent Company Profile (NASDAQ:CTLT)

About Catalent (NASDAQ:CTLT)

Catalent logoCatalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CTLT
  • CUSIP: N/A
  • Web:
  • Market Cap: $5.1 billion
  • Outstanding Shares: 125,175,000
Average Prices:
  • 50 Day Moving Avg: $37.19
  • 200 Day Moving Avg: $33.73
  • 52 Week Range: $21.83 - $42.22
  • Trailing P/E Ratio: 46.85
  • Foreward P/E Ratio: 22.77
  • P/E Growth: 3.09
Sales & Book Value:
  • Annual Revenue: $2.08 billion
  • Price / Sales: 2.45
  • Book Value: $5.79 per share
  • Price / Book: 7.04
  • EBIDTA: $407.5 million
  • Net Margins: 10.02%
  • Return on Equity: 36.29%
  • Return on Assets: 7.36%
  • Average Volume: 1.12 million shs.
  • Short Ratio: 2.73

Frequently Asked Questions for Catalent (NASDAQ:CTLT)

What is Catalent's stock symbol?

Catalent trades on the NASDAQ under the ticker symbol "CTLT."

How were Catalent's earnings last quarter?

Catalent Inc (NASDAQ:CTLT) released its quarterly earnings results on Monday, August, 28th. The company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.08. The firm had revenue of $616.90 million for the quarter, compared to analysts' expectations of $547.48 million. Catalent had a return on equity of 36.29% and a net margin of 10.02%. The company's revenue was up 15.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.52 EPS. View Catalent's Earnings History.

When will Catalent make its next earnings announcement?

Catalent is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Catalent.

Where is Catalent's stock going? Where will Catalent's stock price be in 2017?

10 brokers have issued 1-year target prices for Catalent's stock. Their predictions range from $25.00 to $48.00. On average, they anticipate Catalent's share price to reach $38.60 in the next year. View Analyst Ratings for Catalent.

What are analysts saying about Catalent stock?

Here are some recent quotes from research analysts about Catalent stock:

  • 1. According to Zacks Investment Research, "Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. " (9/1/2017)
  • 2. Jefferies Group LLC analysts commented, "The promise of stability offered by CTLT's diversified revenue stream and LT contracts has been thwarted by FX headwinds, the Beinheim shutdown, and overstocking by DDS segment client. Currency movements are hard to predict or avoid, but management believes the latter two are history. Tuck-in M&A remains a focus to augment mid-single digit revenue growth. We increase estimates and PT slightly. Remain at Hold." (2/27/2017)

Who are some of Catalent's key competitors?

Who are Catalent's key executives?

Catalent's management team includes the folowing people:

  • John R. Chiminski, Chairman of the Board, President, Chief Executive Officer
  • Matthew M. Walsh CPA, Chief Financial Officer, Executive Vice President
  • Aristippos Gennadios, President - Softgel Technologies
  • Wetteny Joseph, President - Clinical Supply Services
  • Barry B. Littlejohns, President - Advanced Delivery Technologies
  • Steven L. Fasman, Senior Vice President, General Counsel and Corporate Secretary
  • William Downie, Senior Vice President - Global Marketing & Sales
  • Lance Miyamoto, Senior Vice President - Human Resources
  • Sharon Johnson, Senior Vice President - Quality, Product Development & Regulatory Affairs
  • Madhavan Balachandran, Director

Who owns Catalent stock?

Catalent's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.01%), Vanguard Group Inc. (8.10%), FMR LLC (6.35%), Janus Henderson Group PLC (5.46%), JPMorgan Chase & Co. (4.11%) and Schroder Investment Management Group (4.03%). Company insiders that own Catalent stock include Blackstone Management Associat, Christine Dolan, Donald E Morel, Jr, John R Chiminski, Matthew M Walsh and Sharon Johnson. View Institutional Ownership Trends for Catalent.

Who sold Catalent stock? Who is selling Catalent stock?

Catalent's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Asset Management Americas Inc., American Century Companies Inc., Redmile Group LLC, Teachers Retirement System of The State of Kentucky, Ameriprise Financial Inc., Goldman Sachs Group Inc. and NGAM Advisors L.P.. Company insiders that have sold Catalent stock in the last year include Christine Dolan, John R Chiminski and Sharon Johnson. View Insider Buying and Selling for Catalent.

Who bought Catalent stock? Who is buying Catalent stock?

Catalent's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, BlackRock Inc., AJO LP, Macquarie Group Ltd., Renaissance Technologies LLC, Teachers Advisors LLC, State Street Corp and Vanguard Group Inc.. View Insider Buying and Selling for Catalent.

How do I buy Catalent stock?

Shares of Catalent can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalent's stock price today?

One share of Catalent stock can currently be purchased for approximately $40.76.

MarketBeat Community Rating for Catalent (NASDAQ CTLT)
Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  149 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  330
MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Catalent (NASDAQ:CTLT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.70)
Consensus Price Target: $38.60 (5.30% downside)

Analysts' Ratings History for Catalent (NASDAQ:CTLT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/21/2017Morgan StanleyUpgradeEqual Weight -> Overweight$29.00 -> $48.00HighView Rating Details
9/20/2017Bank of America CorporationReiterated RatingBuy$40.00 -> $45.00LowView Rating Details
9/20/2017Wells Fargo & CompanyBoost Price TargetOutperform$39.00 -> $43.00LowView Rating Details
9/12/2017Needham & Company LLCInitiated CoverageHold$42.00LowView Rating Details
8/29/2017William BlairReiterated RatingOurperformHighView Rating Details
8/29/2017Jefferies Group LLCReiterated RatingHold$35.00 -> $38.00HighView Rating Details
8/29/2017J P Morgan Chase & CoReiterated RatingBuy$40.00HighView Rating Details
8/29/2017Piper Jaffray CompaniesReiterated RatingBuy$45.00HighView Rating Details
12/1/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$25.00N/AView Rating Details
10/20/2016KeyCorpInitiated CoverageOverweight$29.00N/AView Rating Details
10/18/2016StephensInitiated CoverageOverweight$31.00N/AView Rating Details
2/10/2016Deutsche Bank AGLower Price TargetHold$31.00 -> $24.00N/AView Rating Details
12/9/2015Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 9/25/2015 forward)


Earnings History for Catalent (NASDAQ:CTLT)
Earnings by Quarter for Catalent (NASDAQ:CTLT)
Earnings History by Quarter for Catalent (NASDAQ CTLT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017$0.20N/AView Earnings Details
8/28/2017Q4 2017$0.57$0.65$547.48 million$616.90 millionViewN/AView Earnings Details
5/4/2017Q3 2017$0.36$0.38$470.95 million$532.60 millionViewListenView Earnings Details
2/6/2017Q217$0.27$0.27$474.07 million$483.70 millionViewListenView Earnings Details
11/7/2016Q117$0.13$0.16$430.26 million$442.20 millionViewListenView Earnings Details
8/29/2016Q416$0.53$0.52$498.06 million$532.20 millionViewListenView Earnings Details
5/4/2016Q316$0.31$0.20$425.92 million$438.00 millionViewN/AView Earnings Details
2/9/2016Q216$0.34$0.36$441.99 million$454.90 millionViewN/AView Earnings Details
11/3/2015Q116$0.21$0.14$407.80 million$423.00 millionViewN/AView Earnings Details
9/2/2015Q415$0.58$0.60$496.91 million$510.10 millionViewN/AView Earnings Details
5/5/2015Q3 2015$0.43$0.46$453.25 million$446.60 millionViewN/AView Earnings Details
2/11/2015Q215$0.33$0.44$451.40 million$455.80 millionViewN/AView Earnings Details
11/13/2014Q314$0.20$0.13$411.20 million$418.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Catalent (NASDAQ:CTLT)
2017 EPS Consensus Estimate: $1.32
2018 EPS Consensus Estimate: $1.52
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.12$0.13$0.12
Q2 20173$0.24$0.30$0.26
Q3 20173$0.34$0.37$0.35
Q4 20173$0.55$0.61$0.58
Q1 20182$0.15$0.18$0.17
Q2 20181$0.35$0.35$0.35
Q3 20181$0.39$0.39$0.39
Q4 20181$0.61$0.61$0.61
(Data provided by Zacks Investment Research)


Dividend History for Catalent (NASDAQ:CTLT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Catalent (NASDAQ:CTLT)
Insider Trades by Quarter for Catalent (NASDAQ:CTLT)
Institutional Ownership by Quarter for Catalent (NASDAQ:CTLT)
Insider Trades by Quarter for Catalent (NASDAQ:CTLT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2017Christine DolanSVPSell1,594$38.75$61,767.50View SEC Filing  
8/1/2017Christine DolanSVPSell745$34.85$25,963.25View SEC Filing  
4/25/2017Sharon JohnsonInsiderSell9,160$29.00$265,640.00View SEC Filing  
3/20/2017John R. ChiminskiInsiderSell73,819$28.62$2,112,699.78View SEC Filing  
2/15/2017Donald E. Morel, Jr.DirectorBuy10,000$29.27$292,700.00View SEC Filing  
9/9/2016Blackstone Management AssociatMajor ShareholderSell17,100,705$23.58$403,234,623.90View SEC Filing  
6/9/2016Blackstone Management AssociatMajor ShareholderSell8,785,539$24.51$215,333,560.89View SEC Filing  
5/27/2016Matthew M WalshInsiderSell21,197$28.85$611,533.45View SEC Filing  
8/19/2015John R ChiminskiInsiderSell38,505$33.81$1,301,854.05View SEC Filing  
8/17/2015John R ChiminskiInsiderSell35,550$33.80$1,201,590.00View SEC Filing  
7/20/2015John R ChiminskiInsiderSell33,081$29.40$972,581.40View SEC Filing  
7/6/2015John R ChiminskiInsiderSell33,828$29.34$992,513.52View SEC Filing  
6/11/2015Blackstone Management AssociatMajor ShareholderSell1,844,963$28.13$51,898,809.19View SEC Filing  
6/8/2015Blackstone Management AssociatMajor ShareholderSell12,299,753$28.13$345,992,051.89View SEC Filing  
4/1/2015Scott HoultonInsiderSell16,253$30.61$497,504.33View SEC Filing  
3/27/2015Stephen LeonardInsiderSell31,005$30.13$934,180.65View SEC Filing  
2/17/2015Scott HoultonInsiderSell14,538$27.50$399,795.00View SEC Filing  
2/13/2015Scott HoultonInsiderSell1,400$28.28$39,592.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Catalent (NASDAQ:CTLT)
Latest Headlines for Catalent (NASDAQ:CTLT)
DateHeadline logo$489.28 Million in Sales Expected for Catalent Inc (CTLT) This Quarter - September 25 at 3:46 AM logo$0.18 EPS Expected for Catalent Inc (CTLT) This Quarter - September 23 at 10:26 PM logoCatalent Inc (CTLT) Upgraded to "Overweight" by Morgan Stanley - September 21 at 11:28 PM logoCatalent Inc (CTLT) to Post Q1 2018 Earnings of $0.15 Per Share, William Blair Forecasts - September 21 at 11:20 AM logoTop Analyst Upgrades and Downgrades: AMD, Biogen, Capital One, Intuit, Jinko Solar, Micron, Albermarle, Alnylam and More - September 21 at 9:57 AM logoNoteworthy ETF Outflows: IWO, CTLT, AZPN, GRUB - Nasdaq - September 20 at 11:27 PM logoCatalent Pharma Solutions, Inc. -- Moody's affirms Catalent's B1 CFR; outlook stable - September 20 at 6:26 PM logoCook Medical parent company sells subsidiary for $950M - September 20 at 6:25 PM logoCatalent Inc (CTLT) Price Target Raised to $45.00 - September 20 at 6:24 PM logoCatalent Inc (CTLT) PT Raised to $43.00 - September 20 at 6:24 PM logoContrasting Aralez Pharmaceuticals (ARLZ) & Catalent (CTLT) - September 20 at 8:08 AM logoCatalent To Acquire Privately Held Cook Pharmica For $950 Mln Cash - Quick Facts - September 19 at 5:37 PM logoCatalent (CTLT) to Acquire Cook Pharmica for $950M - September 19 at 5:37 PM logoCatalent to Acquire Cook Pharmica for $950 Million - September 19 at 5:37 PM logoCatalent bolsters biopharma business with Cook Pharmica buy - September 19 at 5:37 PM logoCatalent Dips On $950 Million Acquisition Of Cook Pharmica - September 19 at 5:37 PM logoM&A News: Catalent Inc (CTLT) to Buy Cook Pharmica in $950M Deal - September 19 at 11:14 AM logoM&A News: Catalent Inc (CTLT) to Buy Cook Pharmica in $950M Deal - September 19 at 11:12 AM logoPro-Trader Daily: Earnings Review and Free Research Report: Catalent's Revenue Grew 16%; Adjusted EPS Jumped 25% - September 18 at 5:35 PM logoEarnings Review and Free Research Report: Catalent’s Revenue Grew 16%; Adjusted EPS Jumped 25% - September 18 at 5:35 PM logoCatalent Inc (CTLT) to Post Q1 2018 Earnings of $0.18 Per Share, Jefferies Group Forecasts - September 18 at 4:30 AM logoCatalent Inc (CTLT) Stock Rating Lowered by BidaskClub - September 16 at 5:56 PM logoMerrill Lynch Top Health Care Stock Picks for September: Focus on Large Cap Biotech - September 13 at 6:54 PM logoCatalent Inc (CTLT) Coverage Initiated at Needham & Company LLC - September 12 at 6:28 PM logoCatalent Inc (CTLT) Given Average Recommendation of "Buy" by Analysts - September 12 at 2:52 PM logoCatalent Inc (CTLT) Upgraded at ValuEngine - September 9 at 11:22 PM logoCatalent Inc (CTLT) Stock Rating Upgraded by BidaskClub - September 8 at 12:38 PM logoCatalent Inc (CTLT) Downgraded by KeyCorp to Overweight - September 7 at 10:44 PM logo$490.15 Million in Sales Expected for Catalent Inc (CTLT) This Quarter - September 7 at 12:46 PM logoCatalent Inc (CTLT) Expected to Post Earnings of $0.19 Per Share - September 5 at 4:08 AM logoETFs with exposure to Catalent, Inc. : September 1, 2017 - September 1 at 10:53 PM logoCatalent Inc (CTLT) Stock Rating Lowered by Zacks Investment Research - September 1 at 8:56 PM logoCatalent Inc (CTLT) to Post FY2018 Earnings of $1.49 Per Share, William Blair Forecasts - September 1 at 11:52 AM logoCatalent Inc (CTLT) Stock Rating Reaffirmed by Wells Fargo & Company - August 31 at 2:32 PM logoCatalent Inc (CTLT) SVP Christine Dolan Sells 1,594 Shares - August 31 at 1:18 PM logoEquities Analysts Offer Predictions for Catalent Inc's Q1 2018 Earnings (CTLT) - August 31 at 10:39 AM logoCatalent Inc. (CTLT) Broke Out To A New High On Strong Q4 Earnings - August 30 at 6:40 PM logoStocks With Rising Relative Price Strength: Catalent - August 30 at 6:40 PM logoCatalent, Inc. :CTLT-US: Earnings Analysis: 2017 By the Numbers : August 30, 2017 - August 30 at 6:40 PM logoCatalent, Inc.: Strong price momentum but will it sustain? - August 30 at 6:40 PM logoWhy Movado Group, Catalent, and ImmunoGen Jumped Today - Motley Fool - August 29 at 11:00 PM logo3 Stocks to Watch on Tuesday: Nike Inc (NKE), Finish Line Inc (FINL) and Catalent Inc (CTLT) - - August 29 at 11:00 PM logoEdited Transcript of CTLT earnings conference call or presentation 28-Aug-17 8:45pm GMT - August 29 at 11:00 PM logoBank of America Corporation Reaffirms Buy Rating for Catalent Inc (CTLT) - August 29 at 8:20 PM logoIn Its Best Year Since Going Public, Q4 A Catalyst For Catalent - August 29 at 5:58 PM logoCatalent Inc. (CTLT) Is Challenging The Highs After Q4 Profit Beat - August 29 at 5:58 PM logoWhy Catalent Inc. Rose as Much as 17% This Morning - August 29 at 12:26 PM logoJefferies Group LLC Reiterates "Hold" Rating for Catalent Inc (CTLT) - August 29 at 11:08 AM logoCatalent Inc (CTLT) Rating Reiterated by William Blair - August 29 at 11:08 AM logoJ P Morgan Chase & Co Increases Catalent Inc (CTLT) Price Target to $40.00 - August 29 at 7:58 AM



Catalent (CTLT) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff